Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 Dec;49(6):918-22.
doi: 10.1111/j.1442-200X.2007.02497.x.

Suppression of plasma matrix metalloproteinase-9 following montelukast treatment in childhood asthma

Shih-Sung Chuang  1 , Chih-Hsing Hung, Yi-Ming Hua, Chiung-Hsi Tien, Kuender D Yang, Yuh-Jyh Jong, Shih-Hsien Hsu, Chang-Shen Lin
Affiliations

Suppression of plasma matrix metalloproteinase-9 following montelukast treatment in childhood asthma

Shih-Sung Chuang et al. Pediatr Int. 2007 Dec.

Abstract

Background: Montelukast and ketotifen are commonly prescribed anti-inflammatory medications used in the treatment of childhood asthma.

Methods: To investigate the modulation effect of montelukast and ketotifen, the levels of exhaled nitric oxide (eNO) and plasma matrix metalloproteinase-9 (MMP-9) were analyzed in a group of 30 children with mild persistent asthma.

Results: Patients on montelukast therapy for 8 weeks had significantly decreased levels of eNO and plasma MMP-9, which were associated with improved symptoms and enhanced peak expiratory flow but not significantly associated with increased level of tissue inhibitor metalloproteinase-1 (TIMP-1). In contrast, treatment with ketotifen produced no significant changes in these parameters until 4-6 weeks into the therapy and no effect on plasma MMP-9.

Conclusion: Leukotriene antagonists, such as montelukast, may be better non-steroidal anti-inflammatory drugs for preventing airway inflammation in mild childhood asthma.

PubMed Disclaimer

MeSH terms